Nektar Therapeutics (NKTR) Reaches $58.09 After 6.00% Down Move; Maplelane Capital Trimmed Its Priceline Grp (PCLN) Holding

January 2, 2018 - By Dolores Ford

Maplelane Capital Llc decreased Priceline Grp Inc (PCLN) stake by 73.07% reported in 2017Q3 SEC filing. Maplelane Capital Llc sold 9,500 shares as Priceline Grp Inc (PCLN)’s stock rose 10.44%. The Maplelane Capital Llc holds 3,501 shares with $6.41M value, down from 13,001 last quarter. Priceline Grp Inc now has $86.82B valuation. The stock increased 2.44% or $42.36 during the last trading session, reaching $1780.1. About 189,371 shares traded. The Priceline Group Inc. (NASDAQ:PCLN) has risen 44.63% since January 2, 2017 and is uptrending. It has outperformed by 27.93% the S&P500.

The stock of Nektar Therapeutics (NASDAQ:NKTR) is a huge mover today! The stock decreased 2.73% or $1.63 during the last trading session, reaching $58.09. About 559,455 shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since January 2, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.The move comes after 8 months negative chart setup for the $9.15 billion company. It was reported on Jan, 2 by Barchart.com. We have $54.60 PT which if reached, will make NASDAQ:NKTR worth $548.82 million less.

Maplelane Capital Llc increased Vaneck Vectors Etf Tr stake by 6,500 shares to 20,000 valued at $1.87M in 2017Q3. It also upped Buffalo Wild Wings Inc (NASDAQ:BWLD) stake by 49,501 shares and now owns 50,001 shares. Alibaba Group Hldg Ltd (Call) (NYSE:BABA) was raised too.

Since August 10, 2017, it had 0 insider purchases, and 5 insider sales for $5.60 million activity. 123 shares valued at $231,287 were sold by Tans Gillian on Tuesday, August 15. Docter Jan L sold $4.69M worth of stock.

Among 33 analysts covering Priceline.com (NASDAQ:PCLN), 25 have Buy rating, 0 Sell and 8 Hold. Therefore 76% are positive. Priceline.com had 96 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, August 5 by RBC Capital Markets. On Tuesday, November 7 the stock rating was maintained by Needham with “Buy”. The company was maintained on Wednesday, June 21 by Needham. As per Tuesday, November 8, the company rating was maintained by Benchmark. The firm has “Buy” rating by Jefferies given on Friday, September 15. The stock of The Priceline Group Inc. (NASDAQ:PCLN) earned “Equal Weight” rating by Barclays Capital on Tuesday, November 10. The stock of The Priceline Group Inc. (NASDAQ:PCLN) has “Buy” rating given on Tuesday, January 10 by Citigroup. The company was downgraded on Tuesday, January 5 by Raymond James. The firm has “Buy” rating by Benchmark given on Friday, August 5. The firm earned “Overweight” rating on Wednesday, August 9 by Barclays Capital.

Investors sentiment decreased to 1.03 in Q3 2017. Its down 0.03, from 1.06 in 2017Q2. It turned negative, as 66 investors sold PCLN shares while 320 reduced holdings. 93 funds opened positions while 306 raised stakes. 50.07 million shares or 10.39% more from 45.36 million shares in 2017Q2 were reported. Scharf Invests Ltd Liability Co holds 4.58% of its portfolio in The Priceline Group Inc. (NASDAQ:PCLN) for 103,141 shares. Kepos LP has invested 0.06% in The Priceline Group Inc. (NASDAQ:PCLN). Exane Derivatives holds 0% or 1 shares in its portfolio. Pitcairn invested in 1,577 shares or 0.33% of the stock. Liberty Mutual Gru Asset Mgmt has 0.2% invested in The Priceline Group Inc. (NASDAQ:PCLN) for 2,038 shares. California State Teachers Retirement System holds 82,552 shares or 0.33% of its portfolio. Korea Inv holds 0.17% or 20,668 shares. 167 are owned by Bkd Wealth Ltd Liability Corp. Gmt Capital Corp reported 49,655 shares. 38 are owned by Perkins Coie Tru. Piedmont Advsr Ltd holds 0.41% in The Priceline Group Inc. (NASDAQ:PCLN) or 10,593 shares. Integral Derivatives Limited Liability invested 0.07% in The Priceline Group Inc. (NASDAQ:PCLN). Suntrust Banks Inc holds 0.08% or 8,092 shares. Pub Employees Retirement Systems Of Ohio invested in 0.38% or 40,223 shares. State Bank Of The Ozarks owns 0.32% invested in The Priceline Group Inc. (NASDAQ:PCLN) for 425 shares.

Analysts await The Priceline Group Inc. (NASDAQ:PCLN) to report earnings on February, 26. They expect $14.10 EPS, down 0.77% or $0.11 from last year’s $14.21 per share. PCLN’s profit will be $687.65M for 31.56 P/E if the $14.10 EPS becomes a reality. After $35.22 actual EPS reported by The Priceline Group Inc. for the previous quarter, Wall Street now forecasts -59.97% negative EPS growth.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. They expect $-0.35 earnings per share, down 25.00% or $0.07 from last year’s $-0.28 per share. After $0.37 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59% negative EPS growth.

Since August 16, 2017, it had 0 insider buys, and 17 selling transactions for $17.49 million activity. Labrucherie Gil M had sold 120,000 shares worth $2.93 million on Monday, October 2. ROBIN HOWARD W sold $1.77 million worth of Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, August 16. Gergel Ivan P. had sold 100,000 shares worth $2.41M on Friday, September 29. $109,850 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Lingnau Lutz on Friday, September 22. Hora Maninder also sold $57,110 worth of Nektar Therapeutics (NASDAQ:NKTR) shares. Doberstein Stephen K sold 1,701 shares worth $32,863. Another trade for 4,000 shares valued at $87,440 was made by KUEBLER CHRISTOPHER A on Friday, September 22.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 19 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Buy” rating by Aegis Capital on Tuesday, November 8. The firm has “Buy” rating given on Tuesday, July 18 by J.P. Morgan. The rating was maintained by Jefferies on Wednesday, October 18 with “Buy”. The rating was maintained by Roth Capital on Tuesday, May 30 with “Buy”. Jefferies maintained the stock with “Buy” rating in Wednesday, November 8 report. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Roth Capital on Thursday, July 20. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Monday, November 13 by Roth Capital. Roth Capital maintained the shares of NKTR in report on Wednesday, August 30 with “Buy” rating. TheStreet downgraded Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, August 26 to “Hold” rating. The firm earned “Buy” rating on Wednesday, August 9 by Roth Capital.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $9.15 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Investors sentiment decreased to 1.4 in 2017 Q3. Its down 0.49, from 1.89 in 2017Q2. It dived, as 15 investors sold Nektar Therapeutics shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. Nelson Van Denburg And Campbell Wealth Mgmt Group Inc Ltd Co holds 500 shares or 0% of its portfolio. Federated Invsts Pa owns 1.03 million shares. J Goldman & Ltd Partnership has invested 0.29% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Geode Limited Co accumulated 1.43M shares. First Republic Investment Mgmt Inc holds 25,864 shares. Systematic Management Ltd Partnership has invested 0.36% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). 85,000 are held by Employees Retirement Systems Of Texas. Ls Inv Advsrs Lc reported 0.01% stake. 703,045 were reported by Morgan Stanley. Perigon Wealth Management Ltd Limited Liability Company invested in 0.04% or 5,059 shares. Boston Advsrs Lc holds 0.01% in Nektar Therapeutics (NASDAQ:NKTR) or 19,470 shares. The New York-based Citigroup Inc has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). Citadel Advsrs Lc invested in 118,943 shares or 0% of the stock. World Asset Mngmt, a Michigan-based fund reported 10,281 shares. Tci Wealth has 0% invested in Nektar Therapeutics (NASDAQ:NKTR).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts